Alzheimer’s Disease/Dementia News

Diets with higher inflammatory potential appeared linked to increased risk for incident dementia, according to results of a population-based study published in Neurology.

Estimating treatment effects on caregivers can help determine the cost-effectiveness of treatments for Alzheimer’s disease, according to results of an economic evaluation published in JAMA Network Open.

High and low free thyroxine levels are associated with lower global brain perfusion in adults and could lead to brain diseases, such as dementia, according to a presenter.

Interventions that targeted vascular risk factors in a real-world setting did not appear to reduce dementia incidence in old age, according to study results in a research letter published in JAMA Neurology.

Changes in blood-based biomarkers suggested long-duration spaceflight may pose risks for humans, according to a research letter published in JAMA Neurology.

Adults with autism spectrum disorder were about 2.6 times more likely to be diagnosed with early-onset dementia than adults in the general population, according to a case control study published in Autism Research.

The FDA has granted breakthrough therapy designation to gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, as an Alzheimer’s disease treatment.

Methylphenidate safely and effectively treated apathy in Alzheimer’s disease, according to results of a randomized placebo-controlled clinical trial published in JAMA Neurology.

When diagnosed in young adulthood or during midlife, hypertension was associated with smaller brain volumes and increased dementia risk, researchers reported in Hypertension.

Levetiracetam was well tolerated and appeared to improve performance on spatial memory and executive function tasks among patients with Alzheimer’s disease, according to results of a randomized clinical trial in JAMA Neurology.